Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prasugrel and Wall Street: Lilly Tries to Stop the Bleeding

This article was originally published in RPM Report

Executive Summary

Lilly is in a race against the clock: it is counting on prasugrel to carve out a blockbuster position in the anti-clotting market before 2011. That is when Plavix generics will complicate the anti-clotting marketand Zyprexa generics will complicate Lilly's outlook. But will FDA go along with Lilly's schedule?

You may also be interested in...

Lilly Is Prepared For Potential Prasugrel Advisory Committee

FDA has not yet notified the company of an upcoming advisory panel meeting, executives say.

Prasugrel Delay Could Extend Well Into 2009; FDA Eyes February Cmte. Review

It looks like FDA's decision on Lilly's anti-clotting drug prasugrel won't come before March 2009 at the earliest

"Priority" Review Slow Down: The Prasugrel Delay

FDA is looking at a February advisory committee for the Lilly/Daiichi anti-clotting drug. That would put the review of the "priority" application at 14 months and counting. What does prasugrel mean for the priority review process?

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts